What HemoCue does

HemoCue AB, founded in 1983 and headquartered in Ängelholm, Sweden, is a point-of-care medical diagnostics company operating as a wholly-owned subsidiary of Danaher Corporation. The company develops, manufactures, and markets diagnostic systems and consumables for measuring hemoglobin, glucose, HbA1c, and white blood cells at the point of care. HemoCue serves primary care clinics, hospital departments (emergency, ICU, surgical), blood banks, public health programs, and diabetes management facilities across 130+ countries, employing 430+ people globally. With approximately 140 million tests performed annually, the company positions itself around delivering lab-quality results within seconds to minutes, enabling treatment decisions during the patient consultation rather than after a centralized lab turnaround.

The product portfolio spans three families: Hematology (Hb 801, Hb 201+, Hb 301, Hb 201 DM, WBC System, WBC DIFF System, and Plasma/Low Hb System), Diabetes (HbA1c 501 and four Glucose 201+ variants including DM and room-temperature microcuvette configurations), and accessories (safety lancets, docking stations, cleaners, control materials, and the Martel thermal printer). All systems are built on a proprietary microcuvette technology that accepts approximately 10 µL of capillary or venous blood and uses dual-wavelength measurement for turbidity compensation, yielding lab-quality accuracy at the bedside. The portfolio is protected by granted design and method patents across the US, EU, Japan, China, India, Australia, and Brazil, and is certified to FDA, ISO 13485, IFCC, and NGSP standards.

The business operates a classic razor-and-blade model: capital equipment placements (analyzers) drive recurring consumables revenue through single-use microcuvettes. Go-to-market combines direct enterprise sales via regional subsidiaries in Sweden, Denmark, France, the US, Japan, India, and South Africa with an extensive distributor network reaching Africa, Asia-Pacific, the Middle East, and other regions. Strategic partnerships extend reach beyond direct channels, most notably the Novo Nordisk Changing Diabetes in Children program (400+ clinics in 30 countries), India's Anemia Mukt Bharat initiative (10+ years with MoHFW and AIIMS), and long-tenured distributors including Radiometer Pacific, Abena A/S, and S. Ejazuddin & Co. The Danaher Business System (DBS) underpins operations, while the parent company's diagnostics ecosystem, ESG commitments (EcoVadis Silver, ISO 14001, UN Global Compact), and recent senior leadership refresh from sister Danaher company Radiometer signal continued operational and strategic integration.

Name

HemoCue

Legal name

HemoCue AB

Website

https://hemocue.com

Company type

Private

Founded year

1983

Operating status

Operating

Headcount range

501–1,000 employees

Short description

HemoCue AB, a wholly-owned Danaher subsidiary, develops point-of-care diagnostic systems for hemoglobin, glucose, HbA1c, and white blood cell testing. Serving primary care, hospitals, blood banks, and public health programs across 130+ countries with proprietary microcuvette-based analyzers and consumables.

Ownership category

akta.pro rank

Product category

Point-of-Care Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Hematology POCT (CBC/hemoglobin/hematocrit) (HLAHAOAD)

akta.pro secondary industries

Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH), Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing) (HLAAALAH), Transfusion Medicine & Immunohematology (Blood Bank) (HLAFAMAG)

Keywords

• Point-of-care diagnostics
• Hemoglobin testing systems
• Microcuvette technology
• White blood cell analyzers
• Glucose monitoring devices

Headquarters

HQ city

Ängelholm

HQ country

Sweden

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Point-of-Care Diagnostic Analyzers: Sale of portable diagnostic analyzers including hemoglobin (Hb 201+, Hb 301, Hb 801), glucose (Glucose 201+ series), HbA1c (501), and WBC/WBC DIFF systems. These are capital equipment purchases with varying price points based on system capabilities.
2. Consumables (Microcuvettes and Test Cartridges): Recurring revenue from microcuvettes used with all HemoCue analyzers. Each test requires a single-use microcuvette/cartridge. The company performs 140 million tests per year, indicating substantial consumable revenue. Microcuvettes have shelf lives of 15-24 months depending on packaging.
3. Optional Accessories and Supplies: Sales of safety lancets, cleaning products, control materials, docking stations, and thermal printers from Martel. These support products complement the core analyzer and consumables business.
4. Training and Education Services: HemoCue Web Academy e-learning platform and on-site education services customized to customer needs. Part of customer support and retention strategy.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

HemoCue develops, manufactures, and markets point-of-care medical diagnostic systems and consumables for measuring hemoglobin, glucose, HbA1c, and white blood cell counts. The portfolio spans hematology analyzers (Hb 801, Hb 201+, Hb 301, Hb 201 DM, Plasma/Low Hb, WBC, WBC DIFF), diabetes analyzers (HbA1c 501 and four Glucose 201 variants), and supporting accessories, all based on proprietary microcuvette technology enabling lab-quality results from small (~10 µL) capillary blood samples within seconds to minutes at the point of care.

Product overview

HemoCue offers a comprehensive portfolio of point-of-care diagnostic solutions organized into three product lines: Hematology (hemoglobin and white blood cell testing systems), Diabetes (glucose and HbA1c testing systems), and Optional items (accessories and peripherals). The hematology portfolio includes the Hb 801, Hb 201+, Hb 301, Hb 201 DM (hemoglobin testing), WBC System, WBC DIFF System (white blood cell analysis), and Plasma/Low Hb System. The diabetes portfolio comprises the HbA1c 501 System and four glucose systems (Glucose 201+, Glucose 201 RT, Glucose 201 DM, Glucose 201 DM RT), with DM variants featuring integrated data management and connectivity. Accessories include safety lancets, docking stations, cleaners, control materials, and the Martel thermal printer. All systems utilize proprietary microcuvette technology for lab-quality results at the point of care, with connectivity options including Bluetooth, USB, and POCT1-A interface standards.

Differentiator

Problem solved

Functional benefit

Products and services

• HemoCue Hb 801 System Hemoglobin point-of-care testing system delivering lab-accurate results in less than 1 second with a large display, intuitive symbols, unique let-go-grip design, flexible Bluetooth or USB connectivity, and reagent-free cuvettes with improved open vial stability. Used in primary care, hospital, blood bank, and public health settings.
• HemoCue Hb 201+ System Hemoglobin point-of-care testing system providing lab accuracy and ease of use within 1 minute, with a printer interface and onboard storage for up to 600 results. Recognized as an industry standard for point-of-care hemoglobin testing in primary care, hospitals, and blood banks.
• HemoCue Hb 301 System Hemoglobin testing system optimized for anemia screening in primary care and blood donation settings, delivering lab-quality results within 3 seconds across a 10–40°C operating range suitable for demanding climates.
• HemoCue Hb 201 DM System Hemoglobin point-of-care system with a complete data management solution including bi-directional communication, QC lockout, built-in barcode scanning, and POCT1-A interface for improved patient safety and workflow efficiency in networked clinical environments.
• HemoCue WBC System White blood cell counting system providing total WBC counts at the point of care within 3 minutes from 10 µL capillary or venous samples using proprietary imaging technology. Used for infection detection and screening in emergency, primary care, and blood bank settings.
• HemoCue WBC DIFF System White blood cell analysis system providing total WBC count with 5-part differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils) within 5 minutes, enabling faster clinical decision-making at the point of care using imaging system technology.
• HemoCue Plasma/Low Hb System Photometer system for estimating hemolysis in blood products at the point of care, enabling assessment of sample quality and integrity without laboratory sending. Measuring range of 0.3–30.0 g/L. Used in blood banks and transfusion services.
• HemoCue HbA1c 501 System Fully automated point-of-care HbA1c testing system using boronate affinity assay, delivering reliable results within 5 minutes with on-screen instructions, barcode reader connectivity, and IFCC and NGSP certification. Used for diabetes screening, diagnosis, and monitoring.
• HemoCue Glucose 201+ System Glucose monitoring system used for screening, monitoring, and diagnosis of diabetes mellitus using modified glucose dehydrogenase technology, providing plasma equivalent values within 1 minute with portable battery operation.
• HemoCue Glucose 201 RT System Glucose testing system with room temperature microcuvette storage capability, featuring individually wrapped microcuvettes to minimize contamination and portable battery-operated design for field and resource-limited settings.
• HemoCue Glucose 201 DM System Glucose monitoring system with integrated data management functionality including automatic result transfer, reduced manual entry errors, customizable prompts for patient/operator ID, and USB/LAN POCT1-A connectivity.
• HemoCue Glucose 201 DM RT System Combined data management and room temperature storage glucose system offering high accuracy with instant data connection, customizable prompts, and room temperature microcuvette storage for flexible clinical environments.
• HemoCue Safety Lancet Safety lancet designed to maximize accuracy of capillary blood samples by providing reliable and consistent incision depth, packaged in boxes of 200 lancets for use with HemoCue analyzers.
• HemoCue Docking Station (PDS+/SDS+) Advanced data management docking stations enabling charging and data transfer for Hb 201 DM and Glucose 201 DM analyzers, with PDS+ supporting network connectivity and up to 4 SDS+ secondary stations for multi-analyzer workflow optimization.
• HemoCue Cleaners Lint-free cleaning products pre-moistened with specialized cleaning solution, including HemoCue Cleaner for 201 systems, Hb 301, Plasma/Low Hb, and Glucose analyzers, and HemoCue Cleaner Plus for WBC and WBC DIFF systems.
• Control Material Liquid quality control materials recommended for verifying proper system functioning, sourced from Eurotrol (for all systems except WBC) and R&D Systems (for WBC and WBC DIFF systems).
• Martel MCP7810 Thermal Printer Third-party peripheral thermal printer compatible with Hb 201+, Hb 301, Glucose 201+, Glucose 201 RT, WBC, WBC DIFF, and HbA1c analyzers for printing test results, featuring ultra-compact design and multiple power options including rechargeable NiMH batteries, alkaline batteries, and external universal power supply.

Quantifiable outcome

• 4 tests performed each second worldwide (140 million annually)
• +2 more outcomes

Named customers8 records

Segments7 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Novo NordiskcoreStrategic or Co-development Partner · 1 February 2024February 2024 partnership to improve point-of-care diagnostic testing for children with type 1 diabetes in low- and middle-income countries. Supports Novo Nordisk's Changing Diabetes in Children (CDiC) programme which provided free life-saving medicine to 52,000 children in 2023 and aims to reach 100,000 by 2030. HemoCue HbA1c 501 Systems placed in 400+ clinics across 30 countries in Africa, Latin America, and Southeast Asia.
• India Ministry of Health and Family WelfarecoreStrategic or Co-development PartnerMulti-year partnership supporting the Anemia Mukt Bharat (AMB) program launched in 2018, aimed at reducing anemia prevalence among children, adolescents, and women of reproductive age. HemoCue supports through T3 (Test, Treat and Talk) screening camps hosted by AIIMS throughout India. Company has partnered with India for over 10 years through various national public health initiatives.
• All India Institute of Medical Sciences (AIIMS)coreStrategic or Co-development PartnerPartnership for T3 (Test, Treat and Talk) screening and intervention camps throughout India as part of Anemia Mukt Bharat program. Camps help test, monitor, and track anemia rates among wider populations.
• Abena A/SminorChannel Partner/ Reseller/ DistributorScandinavian distributor of healthcare products. Value HemoCue for high quality, reliability, ease of operation, quick support, and professional product training.
• Alos Paraklet Healthcare LimitedminorChannel Partner/ Reseller/ DistributorGhana-based healthcare distributor providing HemoCue products to clients. Appreciates quality range, consistent supply, and time-saving partnership.
• Radiometer PacificminorChannel Partner/ Reseller/ DistributorAustralia and New Zealand distributor. Long-standing partnership since 2006 with strong support around tenders and global product manager engagement in Pacific markets.
• S. Ejazuddin & Co.minorChannel Partner/ Reseller/ DistributorPakistan-based distributor describing HemoCue as 'the most reliable partner we have had for the past 40 years'.
• Danaher CorporationcoreStrategic or Co-development PartnerHemoCue is a proud part of Danaher, a global life sciences and diagnostics innovator. Benefits include access to Danaher Business System (DBS), continuous improvement culture, broad ecosystem of expertise, technologies, and capabilities. Danaher Sustainability targets guide HemoCue's work on Inclusion and Belonging, energy consumption, greenhouse gas emissions, and waste.
• UN Global CompactminorStrategic or Co-development PartnerHemoCue is a proud signatory member expressing commitment to upholding highest standards within human rights, labor, environment, and anti-corruption.

Scale indicators9 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Radiometer Medical: Sibling Danaher operating company specializing in acute-care diagnostics including blood gas, POC, and immunoassay analyzers. Highly comparable as a Danaher POC diagnostics peer with overlapping hospital customer base and shared DBS operating discipline.
• Masimo: Offers continuous noninvasive hemoglobin monitoring (SpHb) alongside its pulse oximetry and patient monitoring portfolio, competing head-to-head with HemoCue's invasive POC hemoglobin in perioperative and critical care settings.
• Nova Biomedical: U.S.-based POC specialist offering Stat Profile and Prime Plus blood gas/chemistry analyzers — directly comparable as a focused POC diagnostics competitor in hospitals and critical care.
• EKF Diagnostics: U.K.-based POC diagnostics company with Hemo Control and QuikRead hemoglobin and HbA1c analyzers — a focused direct competitor to HemoCue's hemoglobin and HbA1c product lines in primary care, blood bank, and screening segments.
• Werfen (Hemochron / ACL): Specializes in hemostasis and acute-care diagnostics including the Hemochron Signature Elite POC coagulation system — comparable as a focused POC diagnostics company serving hospital critical care and surgical settings.
• Boditech Med: Korean POC diagnostics company offering ichroma hemoglobin, HbA1c, and immunoassay analyzers — overlapping product categories and serves as a regional/emerging POC peer with growing international footprint.

Broad incumbents

• Abbott (i-STAT / Piccolo): Broad incumbent IVD player with i-STAT handheld blood analyzer and Piccolo desktop chemistry platform — overlapping with HemoCue in POC blood gas, chemistry, and hematology, sold into the same hospital and clinic channels.
• Siemens Healthineers (epoc): Large incumbent diagnostics player with the epoc blood analysis system targeting hospital POC use cases (blood gas, hematocrit, glucose) — overlapping with HemoCue's clinical settings and customer segments.
• Roche Diagnostics: Global IVD leader offering cobas POC systems including hemoglobin and HbA1c testing — broad incumbent competitor with overlapping customer base across hospitals, physician offices, and labs.

Emerging players

• Healthy.io: Emerging digital diagnostics company offering smartphone-based urinalysis and chronic kidney disease testing — adjacent emerging player leveraging consumer-grade technology to disrupt traditional POC testing paradigms relevant to HemoCue's markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/HemoCueAB
• Facebookfacebook.com/hemocueab
• LinkedInlinkedin.com/company/38903
• Xx.com/HemoCueAB

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HemoCue